Ibrutinib-associated T-cell pseudolymphoma

Clin Exp Dermatol. 2019 Oct;44(7):828-830. doi: 10.1111/ced.13907. Epub 2019 Jan 8.

Authors

A K H Ho¹, X Q Koh², M M Q Liau³, K B Tan⁴, C L Tan³

Affiliations

¹ School of Medicine, University College Cork, Ireland.
² National University Health System, Republic of Singapore.
³ Division of Dermatology, University Medicine Cluster, National University Health System, Republic of Singapore.
⁴ Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Republic of Singapore.

PMID: 30623454
DOI: 10.1111/ced.13907

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenine / analogs & derivatives
Agammaglobulinaemia Tyrosine Kinase / antagonists & inhibitors*
Aged
Diagnosis, Differential
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Male
Piperidines
Pseudolymphoma / chemically induced*
Pseudolymphoma / pathology
Pyrazoles / adverse effects*
Pyrazoles / therapeutic use
Pyrimidines / adverse effects*
Pyrimidines / therapeutic use
T-Lymphocytes / metabolism
T-Lymphocytes / pathology
Withholding Treatment

Substances

Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Agammaglobulinaemia Tyrosine Kinase
Adenine